A primary listening to in the case might be held at the Brussels Court of First Instance from 9 a.m. (0700 GMT) on Wednesday.
The proceedings might be public and carried out underneath an emergency process, which suggests they may very well be concluded in a matter of weeks, the European Union’s govt Commission stated.
HOW DID IT COME TO THIS?
The EU’s choice to sue AstraZeneca got here after the firm repeatedly reduce provides to the 27-nation bloc, contributing to main delays in Europe’s vaccine rollout, which has lagged these in Britain and the United States.
Under the contract, which was drawn up underneath Belgian legislation, the firm dedicated to creating its “best reasonable efforts” to ship 300 million vaccine doses from December 2020 to June 2021, together with 180 million in the present second quarter.
However, the firm stated in a press release on March 12 that it will purpose to ship solely one-third of that 300 million complete, of which about 70 million can be in the second quarter.
Every week later, Brussels despatched a authorized letter to AstraZeneca, in the first step of potential court docket proceedings.
WHAT DOES ASTRAZENECA SAY?
AstraZeneca says the EU’s authorized motion is with out benefit, argues that it complied with the contract, and has pledged to defend itself robustly in court docket.
WHAT’S IN IT FOR THE EU?
EU officers say the purpose of the lawsuit is to compel AstraZeneca to ship extra vaccines than the quantity it has stated it will purpose to ship.
The EU desires as many as doable of the promised 300 million doses, however would accept 130 million by the finish of June, an EU supply accustomed to the discussions informed Reuters.
Brussels will even need AstraZeneca to elucidate to the court docket the way it spent greater than 224 million euros ($270 million) granted by the EU final September to purchase vaccine elements, and for which the bloc stated the firm didn’t present adequate paperwork confirming the purchases.
If profitable in court docket, the EU would ship a warning to different vaccine suppliers. Pharmaceutical Johnson & Johnson has warned the EU it might not ship the 55 million doses of its COVID-19 vaccine that it contracted to provide in the second quarter.
WHAT ARE THE RISKS FOR THE EU?
Some member states have been initially reluctant to sue AstraZeneca on the grounds that it will take too lengthy and, reasonably than velocity up deliveries, solely exacerbate tensions with an organization they’re nonetheless relying on for his or her vaccine campaigns.
If the EU loses its case in the Brussels court docket, it will be a public relations blow on high of criticism over its dealing with of vaccine buy agreements and rollout of photographs.
HOW FAR IS THE EU STILL RELYING ON ASTRAZENECA?
The AstraZeneca shot developed by Oxford University was speculated to be the fundamental one in the EU vaccination marketing campaign for the first half of this yr.
However, the EU has now distanced itself from the firm attributable to the provide issues and considerations over the efficacy and security of the vaccine.
The bloc has forgone one other 100 million AstraZeneca photographs that it had an possibility to purchase underneath the contract signed final August, and is now relying totally on the Pfizer-BioNTech vaccine to inoculate at the very least 70% of EU adults by the finish of July.
Still, whereas the AstraZeneca shot has been linked to very uncommon circumstances of blood clots, the EU drug regulator has advisable its use to comprise the unfold of COVID-19.